Your session is about to expire
← Back to Search
DOVATO Switch for HIV/AIDS Management (Sound Trial)
Sound Trial Summary
This trial is testing whether it's safe to switch HIV patients who are already taking Bitarvy and are virologically suppressed to Dovato.
Sound Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Sound Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have liver disease that is not stable or cirrhosis, or you have known issues with your bile ducts (except for harmless conditions like Gilbert's syndrome or asymptomatic gallstones).You are allergic to dolutegravir or lamivudine.
- Group 1: dolutegravir/lamivudine
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the process of enrolling participants ongoing for this trial?
"As indicated on clinicaltrials.gov, this specific trial is no longer searching for participants as it was posted on September 26th 2021 and last updated May 3rd 2022. Nevertheless, over six hundred eighty five alternative medical studies are currently recruiting patients."
What is the current enrollment for this experiment?
"This medical investigation is no longer searching for volunteers. The trial was first published on September 26th 2021 and amended May 3rd 2022. Alternatively, 636 HIV-related clinical trials are still recruiting patients while 49 studies focus specifically on Dolutegravir/Lamivudine therapies."
What other research has been done to explore the efficacy of Dolutegravir/Lamivudine?
"Currently, there are 49 clinical trials investigating the effectiveness of Dolutegravir/Lamivudine. Of those studies, 17 progress to Phase 3 and involve 356 different medical centres worldwide--the majority being situated in Toronto, Ontario."
Has the FDA endorsed Dolutegravir/Lamivudine for medicinal use?
"The safety of Dolutegravir/Lamivudine is assessed to be a 3, as this medication has already achieved approval in Phase 4 trials."
Share this study with friends
Copy Link
Messenger